← Product Code [JTN](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JTN) · K250956 # HardyDisk AST Gepotidacin 10µg (GEP10) (K250956) _Hardy Diagnostics · JTN · Jun 26, 2025 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JTN/K250956 ## Device Facts - **Applicant:** Hardy Diagnostics - **Product Code:** [JTN](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JTN.md) - **Decision Date:** Jun 26, 2025 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1620 - **Device Class:** Class 2 - **Review Panel:** Microbiology - **Attributes:** PCCP ## Indications for Use HardyDisk AST disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. Standardized methods for agar diffusion testing have been described for Enterobacterales, Staphylococcus spp., Pseudomonas spp., Acinetobacter spp., Listeria monocytogenes, Enterococcus spp., and by modified procedures, Candida spp., Haemophilus spp., Neisseria gonorrhoeae, Neisseria meningitidis and Streptococcus spp., including Streptococcus pneumoniae. Use of HardyDisk AST Gepotidacin 10μg (GEP10) for in vitro agar diffusion susceptibility testing is indicated when there is the need to determine the susceptibility of Enterobacterales, Staphylococcus saprophyticus, and Enterococcus faecalis to gepotidacin, as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). HardyDisk AST Gepotidacin at concentration 10μg demonstrated acceptable performance to determine the zone diameter (mm) of gepotidacin against the following microorganisms: Enterobacterales (Citrobacter freundii complex, Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca/Raoultella ornithinolytica, Morganella morganii, Proteus mirabilis, Providencia rettgeri), Enterococcus faecalis, Staphylococcus saprophyticus. ## Device Story HardyDisk AST Gepotidacin 10μg is a 6 mm diameter filter paper disk impregnated with 10μg of the antimicrobial agent gepotidacin. Used in clinical microbiology laboratories for semi-quantitative in vitro susceptibility testing via the Kirby-Bauer agar diffusion method. The process involves inoculating a Mueller Hinton agar plate with a standardized bacterial suspension (0.5 McFarland), placing the disk onto the agar surface, and incubating for 16-18 hours at 35°C. The healthcare provider measures the resulting zone of inhibition (mm) and compares it against FDA-recognized susceptibility test interpretive criteria (STIC) to categorize the organism as susceptible, intermediate, or resistant. This information assists clinicians in selecting appropriate antimicrobial therapy for patients. ## Clinical Evidence No clinical data. Performance supported by stability, quality control, disk-to-MIC correlation, and reproducibility studies conducted in accordance with CDER guidance for antimicrobial susceptibility test devices. Data evaluated by CDER to establish FDA STIC breakpoints. ## Technological Characteristics Antimicrobial susceptibility test disc; 10µg gepotidacin concentration; paper-based form factor; utilizes Kirby-Bauer agar diffusion principle; manual measurement of zone diameter; in vitro diagnostic use. ## Regulatory Identification An antimicrobial susceptibility test disc is a device that consists of antimicrobic-impregnated paper discs used to measure by a disc-agar diffusion technique or a disc-broth elution technique the in vitro susceptibility of most clinically important bacterial pathogens to antimicrobial agents. In the disc-agar diffusion technique, bacterial susceptibility is ascertained by directly measuring the magnitude of a zone of bacterial inhibition around the disc on an agar surface. The disc-broth elution technique is associated with an automated rapid susceptibility test system and employs a fluid medium in which susceptibility is ascertained by photometrically measuring changes in bacterial growth resulting when antimicrobial material is eluted from the disc into the fluid medium. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY ## I Background Information: A 510(k) Number K250956 B Applicant Hardy Diagnostics C Proprietary and Established Names HardyDisk AST Gepotidacin 10μg (GEP10) D Regulatory Information | Product Code(s) | Classification | Regulation Section | Panel | | --- | --- | --- | --- | | JTN | Class II | 21 CFR 866.1620 - Antimicrobial Susceptibility Test Disc | MI - Microbiology | ## II Submission/Device Overview: ### A Purpose for Submission: In this Traditional 510(k) submission, Hardy Diagnostics seeks the following: 1. Obtain a substantial equivalence determination for gepotidacin antimicrobial susceptibility test disk. 2. Establish a Pre-Determined Change Control Plan (PCCP) to address future revisions to device labeling in response to breakpoint changes that are recognized on the FDA STIC webpage. ### B Measurand: Gepotidacin 10μg ### C Type of Test: Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 www.fda.gov {1} Antimicrobial Susceptibility Test Disks ## III Intended Use/Indications for Use: ### A Intended Use(s): See Indications for Use below. ### B Indication(s) for Use: HardyDisk AST disks are used for semi-quantitative *in vitro* susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. Standardized methods for agar diffusion testing have been described for Enterobacterales, *Staphylococcus* spp., *Pseudomonas* spp., *Acinetobacter* spp., *Listeria monocytogenes*, *Enterococcus* spp., and by modified procedures, *Candida* spp., *Haemophilus* spp., *Neisseria gonorrhoeae*, *Neisseria meningitidis* and *Streptococcus* spp., including *Streptococcus pneumoniae*. Use of HardyDisk AST Gepotidacin 10μg (GEP10) for *in vitro* agar diffusion susceptibility testing is indicated when there is the need to determine the susceptibility of Enterobacterales, *Staphylococcus saprophyticus*, and *Enterococcus faecalis* to gepotidacin, as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). HardyDisk AST Gepotidacin at concentration 10μg demonstrated acceptable performance to determine the zone diameter (mm) of gepotidacin against the following microorganisms: - Enterobacterales (*Citrobacter freundii* complex, *Escherichia coli*, *Klebsiella pneumoniae*, *Citrobacter koseri*, *Klebsiella aerogenes*, *Klebsiella oxytoca*/Raoultella ornithinolytica, *Morganella morganii*, *Proteus mirabilis*, *Providencia rettgeri*) - *Enterococcus faecalis* - *Staphylococcus saprophyticus* ### C Special Conditions for Use Statement(s): Rx - For Prescription Use Only ### D Special Instrument Requirements: Not applicable. ## IV Device/System Characteristics: ### A Device Description: HardyDisk AST Gepotidacin 10μg (GEP10) is a high quality 6 mm diameter white filter paper disk that is impregnated with 10μg gepotidacin. The disks are clearly marked on both sides with GEP10, designating the agent and the drug content. The disks are supplied in plastic cartridges K250956 - Page 2 of 7 {2} containing 50 disks each. HardyDisk AST Gepotidacin $10\mu \mathrm{g}$ (GEP10) is intended to be used for in vitro agar diffusion susceptibility testing. # B Principle of Operation: The HardyDisk AST Disk is based on the agar diffusion (Kirby-Bauer) methodology. It utilizes dried filter paper disks impregnated with a known concentration of an antimicrobial agent that are placed onto the test medium surface. Three to five similar colonies are transferred to $4 - 5\mathrm{mL}$ of a suitable broth medium. The broth is incubated at $35^{\circ}\mathrm{C}$ for 2-6 hours to develop a turbidity that exceeds or is equivalent to a $0.5\mathrm{McFarland}$ standard. Alternatively, a direct broth or saline suspension of colonies may be prepared from an overnight culture. The final inoculum density should be equivalent to a $0.5\mathrm{McFarland}$ turbidity standard. The inoculum density may also be standardized photometrically. Within 15 minutes of inoculum preparation, the Mueller Hinton agar plate is streaked with an inoculated swab to obtain an even inoculation of organism. Disks are aseptically placed onto the agar surface with a disk dispenser and the disks are pressed down with a sterile needle or forceps to make contact with the agar surface. Agar plates are incubated in an ambient air incubator at $35 \pm 2^{\circ} \mathrm{C}$ for 16-18 hours. After incubation, the agar medium is examined for a zone of inhibition around the disks. The zones of inhibition are measured to the nearest millimeter and interpreted qualitatively in accordance with the recognized zone size interpretive criteria for the antimicrobial agent being tested. # V Substantial Equivalence Information: # A Predicate Device Name(s): HardyDisk AST Cefiderocol $30\mu \mathrm{g}$ (FDC30) # B Predicate 510(k) Number(s): K241060 # C Comparison with Predicate(s): | Device & Predicate Device(s): | Device K250956 | Predicate K241060 | | --- | --- | --- | | Device Trade Name | HardyDisk AST Gepotidacin 10μg (GEP10) | HardyDisk AST Cefiderocol 30μg (FDC30) | | General Device Characteristic Similarities | | | | Intended Use | Semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of | Same | K250956 - Page 3 of 7 {3} K250956 - Page 4 of 7 | Device & Predicate Device(s): | Device K250956 | Predicate K241060 | | --- | --- | --- | | | rapidly growing and certain fastidious bacterial pathogens. | | | Test Method | Antimicrobial susceptibility testing using paper disks impregnated with an antimicrobial agent | Same | | Methodology | Kirby-Bauer Disk Diffusion Susceptibility Test Protocol requires the user to determine categorical interpretations (S/I/R) using the measured zone diameters. | Same | | Inoculum | Prepared from pure isolated colonies to match the turbidity equivalent of a 0.5 McFarland in Tryptic Soy Broth. | Same | | Inoculum Method | Dip a sterile swab into the prepared inoculum and streak an appropriate agar plate’s surface three times. Add the disks impregnated with the antimicrobial agent to the surface of the plate. The temperature, atmospheric conditions and duration of incubation is dependent on the organism tested. | Same | | Reading Method | The user will interpret the zone diameters according to the established interpretive criteria for the drug. | Same | | General Device Characteristic Differences | | | | Antimicrobial Agent | Gepotidacin | Cefiderocol | {4} | Device & Predicate Device(s): | Device K250956 | Predicate K241060 | | --- | --- | --- | | Concentration | 10μg | 30μg | VI Standards/Guidance Documents Referenced: - CLSI M02-14th ed. Performance Standards for Antimicrobial Disk Susceptibility Tests (March 2024). - CLSI M100-35th ed. Performance Standards for Antimicrobial Susceptibility Testing (January 2025). VII Performance Characteristics (if/when applicable): The premarket submission for HardyDisk AST Gepotidacin 10μg (GEP10) included a letter dated October 7, 2024, indicating the right of reference to NDA 218230. Descriptive characteristics were sufficient for the HardyDisk AST Gepotidacin 10μg (GEP10) disk based on data from microbiology disk studies evaluated by CDER which were used to generate the breakpoints identified by FDA on the susceptibility test interpretive criteria (STIC) webpage. In addition, CDER concurred with the disk QC ranges that were established by CLSI. The disk data used to support this submission included data from testing organisms shown to be active in vitro and/or in clinical infections within the spectrum of activity of gepotidacin. Data obtained from stability, quality control, disk to MIC correlation, and reproducibility (from disk content optimization) studies were generated in accordance with the CDER Clinical/Antimicrobial guidance, Microbiology Data for Systemic Antibacterial Drugs-Development, Analysis, and Presentation to ensure precise, accurate, and reproducible results. For this review, the interpretive criteria are applied to Enterobacterales, Staphylococcus saprophyticus, and Enterococcus faecalis according to the FDA STIC website. As required under 511A(2)(2)(B) of the Federal Food, Drug and Cosmetic Act, the following statement is included in the Precautions section of the HardyDisk AST Gepotidacin 10μg (GEP10) package insert: Per the FDA-Recognized Susceptibility Test Interpretive Criteria website, the safety and efficacy of antimicrobial drugs, for which antimicrobial susceptibility is tested by this AST device, may or may not have been established in adequate and well-controlled clinical trials for treating clinical infections due to microorganisms outside of those found in the indications and usage in the drug label. The clinical significance of susceptibility information in those instances is unknown. The approved labeling for specific antimicrobial drugs provides the uses for which the antimicrobial drug is approved. Non-susceptible Isolates Tested: Due to the lack of an interpretive category other than susceptible for gepotidacin with Staphylococcus saprophyticus and Enterococcus faecalis, the following limitation was included in the device labeling: K250956 - Page 5 of 7 {5} The current absence of resistant isolates for Staphylococcus saprophyticus and Enterococcus faecalis precludes defining any results other than "Susceptible". Isolates yielding results other than "Susceptible" should be submitted to a reference laboratory for further testing. ## A Analytical Performance: 1. Precision/Reproducibility: Not applicable. 2. Linearity: Not applicable. 3. Analytical Specificity/Interference: Not applicable. 4. Assay Reportable Range: Not applicable. 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Not applicable. 6. Detection Limit: Not applicable. 7. Assay Cut-Off: Not applicable. ## B Comparison Studies: 1. Method Comparison with Predicate Device: Not applicable. 2. Matrix Comparison: Not applicable. ## C Clinical Studies: 1. Clinical Sensitivity: Not applicable. 2. Clinical Specificity: Not applicable. K250956 - Page 6 of 7 {6} 3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable. # D Clinical Cut-Off: Not applicable. # E Expected Values/Reference Range: The FDA-identified susceptibility interpretive criteria for gepotidacin are listed below in Table 1. Table 1. FDA-Identified Disk Diffusion Interpretive Criteria (zone diameter in mm) for Gepotidacin | Organisms | Interpretive Criteria (mm)a | | | | --- | --- | --- | --- | | | Susceptible (S) | Intermediate (I) | Resistant (R) | | Enterobacterales | ≥12 | 8–11 | ≤7 | | Staphylococcus saprophyticus | ≥23 | - | - | | Enterococcus faecalis | ≥14 | - | - | a FDA STIC Webpage # VIII Proposed Labeling: The labeling supports the finding of substantial equivalence for this device. # IX Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. To support the implementation of changes to FDA-recognized susceptibility test interpretive criteria (i.e., breakpoints), this submission included a predetermined change control plan (PCCP) that was reviewed and accepted by FDA. This PCCP addresses future revisions to device labeling in response to breakpoint changes that are recognized on the FDA STIC webpage (https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm410971.htm). The PCCP outlined the specific procedures and acceptance criteria that Hardy Diagnostics intends to use to evaluate the HardyDisk AST Gepotidacin $10\mu \mathrm{g}$ (GEP10) when revised breakpoints for gepotidacin are published on the FDA STIC webpage. The PCCP included with the submission indicated that if specific criteria are met, Hardy Diagnostics will update the HardyDisk AST Gepotidacin $10\mu \mathrm{g}$ (GEP10) device label to include the new breakpoints. K250956 - Page 7 of 7 --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JTN/K250956](https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JTN/K250956) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com